Preface
Hepatocellular carcinoma: what is happening everywhere?
Chinese Clinical Oncology
2013;
2
(4)
:31
.
(16 December 2013)
Review Articles
Viral hepatitis, non-alcoholic fatty liver disease and alcohol as risk factors for hepatocellular carcinoma
Chinese Clinical Oncology
2013;
2
(4)
:32
.
(16 December 2013)
A review of hepatocellular carcinoma (HCC) staging systems
Chinese Clinical Oncology
2013;
2
(4)
:33
.
(16 December 2013)
Management of liver cirrhosis in patients with hepatocellular carcinoma
Chinese Clinical Oncology
2013;
2
(4)
:34
.
(16 December 2013)
Hepatocellular carcinoma in the modern era: transplantation, ablation, open surgery or minimally invasive surgery?—A multidisciplinary personalized decision
Chinese Clinical Oncology
2013;
2
(4)
:35
.
(16 December 2013)
Percutaneous therapies of hepatocellular carcinoma—an update
Chinese Clinical Oncology
2013;
2
(4)
:36
.
(16 December 2013)
Systemic therapy for hepatocellular carcinoma
Chinese Clinical Oncology
2013;
2
(4)
:37
.
(16 December 2013)
Features and treatment options of Chinese hepatocellular carcinoma
Chinese Clinical Oncology
2013;
2
(4)
:38
.
(16 December 2013)
Status of hepatocellular carcinoma in South Korea
Chinese Clinical Oncology
2013;
2
(4)
:39
.
(16 December 2013)
Current status of hepatocellular carcinoma in Japan
Chinese Clinical Oncology
2013;
2
(4)
:40
.
(16 December 2013)
Hepatocellular carcinoma in India
Chinese Clinical Oncology
2013;
2
(4)
:41
.
(16 December 2013)
Status of hepatocellular carcinoma in Gulf region
Chinese Clinical Oncology
2013;
2
(4)
:42
.
(16 December 2013)
Risk factors for developing hepatocellular carcinoma in Egypt
Chinese Clinical Oncology
2013;
2
(4)
:43
.
(16 December 2013)
Status of hepatocellular cancer in Europe
Chinese Clinical Oncology
2013;
2
(4)
:44
.
(16 December 2013)
Current status of hepatocellular carcinoma in the United States
Chinese Clinical Oncology
2013;
2
(4)
:45
.
(16 December 2013)
Disclosure:
The focused issue “Hepatocellular carcinoma” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Ghassan K. Abou-Alfa served as the unpaid Guest Editor for the focused issue.
